EGFR and non-small cell lung carcinoma: To date, two tests based on plasma ctDNA analysis have been FDA-approved for clinical use: the testing of EGFR mutations in patients with NSCLC and the methylation of the SEPT9 promoter as screening for colorectal cancer [56, 64, 67, 70].